or years, diabetes medicines were mainly seen as treatments for blood sugar control. But new research is opening an interesting question: could some of these medications also support brain health as people age? Scientists are paying more attention to the connection between type 2 diabetes, metabolism, inflammation, and dementia. The brain needs a steady supply of energy, healthy blood vessels, and low levels of chronic inflammation to function well. When blood sugar and insulin regulation are disrupted for years, the brain may also be affected. This is why researchers are now studying whether certain diabetes drugs may do more than manage glucose — they may also be linked to a lower risk of cognitive decline and dementia. The link between diabetes and dementia Type 2 diabetes does not only affect blood sugar. Over time, it can also affect blood vessels, inflammation, heart health, and the way the body uses energy. These same systems are important for brain health. Researchers have found that people with type 2 diabetes have a higher risk of developing dementia. A McGill University report notes that type 2 diabetes increases dementia risk by about 60%, which is why scientists are looking for better prevention strategies in people with diabetes. This does not mean everyone with diabetes will develop dementia. It means that long-term metabolic health matters — and improving it may also help protect the brain. Which diabetes drugs are researchers studying? Some of the most discussed medicines are called GLP-1 receptor agonists. These include drugs used for type 2 diabetes and, in some cases, weight management. They help regulate blood sugar, reduce appetite, and may influence inflammation and blood vessel health. According to the Alzheimer’s Association, large real-world healthcare datasets suggest that GLP‑1 receptor agonists may be associated with a lower dementia risk compared with some other diabetes medications, although researchers still need stronger clinical trials to confirm the effect. Another group, called DPP-4 inhibitors, is also being studied. A large McGill University study of more than 450,000 patients found that two incretin-based medication classes — GLP-1 receptor agonists and DPP-4 inhibitors — were associated with reduced dementia risk in people with type 2 diabetes. In that study, DPP-4 inhibitors were linked to a 23% lower dementia risk compared with sulfonylureas, while GLP-1 drugs showed a similar pattern but with less certainty because fewer patients were using them. Why might these medicines affect the brain?

Why might these medicines affect the brain?

Researchers are still investigating the exact reasons, but several ideas are being studied.

First, better blood sugar control may reduce damage to small blood vessels, including those in the brain. Healthy blood vessels are important because the brain depends on oxygen and nutrients every second.

Second, some diabetes medications may help reduce inflammation. Chronic inflammation is believed to play a role in many age-related diseases, including cognitive decline.

Third, these medications may improve metabolism. The brain uses a lot of energy, and poor metabolic health may affect memory, focus, and long-term brain function.

Finally, weight, heart health, and blood pressure are also connected to dementia risk. Some diabetes medicines can affect these areas, which may indirectly support brain health.

What about semaglutide and drugs like Ozempic?

Semaglutide has received a lot of attention because it is widely used for type 2 diabetes and weight management. Some observational studies have linked semaglutide use with lower dementia risk in people with type 2 diabetes. A Case Western Reserve University study analyzed electronic health records from nearly 1.7 million patients with type 2 diabetes and found that patients prescribed semaglutide had a lower risk of Alzheimer’s disease-related dementia compared with several other anti-diabetic medications. However, the researchers also said randomized clinical trials are needed before making firm conclusions.

This is an important point: observational studies can show a link, but they cannot fully prove that the drug itself caused the lower risk.

Important: this does not mean it is a dementia cure

Even though the research is promising, diabetes drugs should not be presented as a cure for dementia or Alzheimer’s disease.

In 2026, Nature Medicine reported that semaglutide did not slow the clinical progression of Alzheimer’s disease in phase 3 EVOKE trials. This means the drug may still be studied for prevention or risk reduction, but it should not be described as a proven Alzheimer’s treatment.

That difference matters.

A medicine may be linked to lower future risk in some people, but that does not mean it can reverse dementia after it has already developed.

Metformin is also being studied

Metformin, one of the oldest and most commonly used diabetes medicines, is also being researched for brain health. A 2026 study in Communications Medicine compared multiple diabetes therapies and found that metformin showed strong potential in pathways related to diabetes-associated Alzheimer’s disease. The authors emphasized that diabetes therapies may differ in how they affect brain-related biological pathways.

This shows that the story is not about one “miracle drug.” It is about understanding how different diabetes treatments may affect the aging brain in different ways.

What should people do with this information?